The intersection of immune deficiency and autoimmunity

Current Opinion in Rheumatology

Volumn 26, Issue 5, 2014, Pages 570-578

  Maggadottir, Solrun M ^a   Sullivan, Kathleen E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

autoantibody; inflammation; regulatory T cell; thymus; tolerance

Indexed keywords

APOPTOSIS; AUTOIMMUNITY; CELL PROLIFERATION; COMPLEMENT DEFICIENCY; DISEASE ASSOCIATION; HOMEOSTASIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTOPENIA; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; B LYMPHOCYTE; CELL SURVIVAL; IMMUNOLOGY; PATHOLOGY;

APOPTOSIS; AUTOIMMUNITY; B-LYMPHOCYTES; CELL SURVIVAL; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOPENIA; SELF TOLERANCE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84905495063     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000091     Document Type: Review

References (87)

1. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2011; 2:1-26; article 54.
2. Liston A, Lesage S, Wilson J, et al. Aire regulates negative selection of organspecific T cells. Nat Immunol 2003; 4:350-354.
3. Kisand K, Peterson P, Laan M. Lymphopenia-induced proliferation in airedeficient mice helps to explain their autoimmunity and differences from human patients. Front Immunol 2014; 5:1-10; article 51.
4. Su MA, Anderson MS. Monogenic autoimmune diseases: insights into selftolerance. Pediatr Res 2009; 65:20R-25R.
5. Laakso SM, Kekalainen E, Rossi LH, et al. IL-7 dysregulation and loss of CD8+ T cell homeostasis in the monogenic human disease autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Immunol 2011; 187:2023-2030.
6. Kisand K, Lilic D, Casanova JL, et al. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 2011; 41:1517-1527.
7. Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116:1713-1722.
8. Lyon MF, Peters J, Glenister PH, et al. The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott-Aldrich syndrome. Proc Natl Acad Sci U S A 1990; 87:2433-2437.
9. Notarangelo LD, Gambineri E, Badolato R. Immunodeficiencies with autoimmune consequences. Adv Immunol 2006; 89:321-370.
10. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 2007; 120:744-750.
11. Goudy K, Aydin D, Barzaghi F, et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol 2013; 146:248-261.
12. Cohen AC, Nadeau KC, Tu W, et al. Cutting edge: decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol 2006; 177:2770-2774.
13. Kanai T, Seki S, Jenks JA, et al. Identification of STAT5A and STAT5B target genes in human T cells. PLoS One 2014; 9:e86790.
14. Hwa V, Nadeau K, Wit JM, Rosenfeld RG. STAT5b deficiency: lessons from STAT5b gene mutations. Best Pract Res Clin Endocrinol Metab 2011; 25:61-75.
15. Nadeau K, Hwa V, Rosenfeld RG. STAT5b deficiency: an unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease. J Pediatr 2011; 158:701-708.
16. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377.
17. Ochs HD, Notarangelo LD. X-linked immunodeficiencies. Curr Allergy Asthma Rep 2004; 4:339-348.
18. Lee KG, Xu S, Wong ET, et al. Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells. J Biol Chem 2008; 283:11189-11198.
19. Kubo T, Uchida Y, Watanabe Y, et al. Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med 2009; 206:1971-1982.
20. Yong PF, Workman S, Wahid F, et al. Selective deficits in blood dendritic cell subsets in common variable immunodeficiency and X-linked agammaglobulinaemia but not specific polysaccharide antibody deficiency. Clin Immunol 2008; 127:34-42.
21. Lougaris V, Baronio M, Vitali M, et al. Bruton tyrosine kinase mediates TLR9- dependent human dendritic cell activation. J Allergy Clin Immunol 2014; 133:1644-1650.
22. Ng YS, Wardemann H, Chelnis J, et al. Bruton's tyrosine kinase is essential for human B cell tolerance. J Exp Med 2004; 200:927-934.
23. Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008; 20:632-638.
24. Meffre E. The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann N Y Acad Sci 2011; 1246: 1-10.
25. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277-286.
26. Bonhomme D, Hammarstrom L, Webster D, et al. Impaired antibody affinity maturation process characterizes a subset of patients with common variable immunodeficiency. J Immunol 2000; 165:4725-4730.
27. Warnatz K, Denz A, Drager R, et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 2002; 99:1544-1551.
28. Sanchez-Ramon S, Radigan L, Yu JE, et al. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin Immunol 2008; 128:314-321.
29. Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111:77-85.
30. Isnardi I, Ng YS, Menard L, et al. Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood 2010; 115:5026-5036.
31. Romberg N, Chamberlain N, Saadoun D, et al. CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest 2013; 123:4283-4293.
32. Stohl W, Xu D, Kim KS, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005; 52:2080-2091.
33. Rieck M, Arechiga A, Onengut-Gumuscu S, et al. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007; 179:4704-4710.
34. Chew GY, Sinha U, Gatenby PA, et al. Autoimmunity in primary antibody deficiency is associated with protein tyrosine phosphatase nonreceptor type 22 (PTPN22). J Allergy Clin Immunol 2013; 131:1130-1135.
35. Arandi N, Mirshafiey A, Abolhassani H, et al. Frequency and expression of inhibitory markers of CD4(+) CD25(+) FOXP3(+) regulatory T cells in patients with common variable immunodeficiency. Scand J Immunol 2013; 77:405-412.
36. Orange JS, Levy O, Geha RS. Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappaB activation. Immunol Rev 2005; 203:21-37.
37. Hanson EP, Monaco-Shawver L, Solt LA, et al. Hypomorphic nuclear factorkappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol 2008; 122:1169-1177; e1116.
38. Notarangelo LD, Lanzi G, Peron S, et al. Defects of class-switch recombination. J Allergy Clin Immunol 2006; 117:855-864.
39. Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J Clin Immunol 2008; 28 (Suppl 1):S62-S66.
40. Kumanogoh A, Wang X, Lee I, et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol 2001; 166:353-360.
41. White AJ, Withers DR, Parnell SM, et al. Sequential phases in the development of Aire-expressing medullary thymic epithelial cells involve distinct cellular input. Eur J Immunol 2008; 38:942-947.
42. Rigaud S, Fondaneche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006; 444:110-114.
43. Ma CS, Nichols KE, Tangye SG. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu Rev Immunol 2007; 25:337-379.
44. Nichols KE, Ma CS, Cannons JL, et al. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev 2005; 203:180-199.
45. Rezaei N, Mahmoudi E, Aghamohammadi A, et al. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br J Haematol 2011; 152:13-30.
46. Menard L, Cantaert T, Chamberlain N, et al. Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance. J Allergy Clin Immunol 2014; 133:1149-1161.
47. Notarangelo LD, Miao CH, Ochs HD. Wiskott-Aldrich syndrome. Curr Opin Hematol 2008; 15:30-36.
48. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol 2010; 10:182-192.
49. Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010; 115:3231-3238.
50. Maillard MH, Cotta-de-Almeida V, Takeshima F, et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. J Exp Med 2007; 204:381-391.
51. Castiello MC, Bosticardo M, Pala F, et al. Wiskott-Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans. J Autoimmun 2014; 50:42-50.
52. Rakhmanov M, Keller B, Gutenberger S, et al. Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proc Natl Acad Sci U S A 2009; 106:13451-13456.
53. Oliveira JB, Gupta S. Disorders of apoptosis: mechanisms for autoimmunity in primary immunodeficiency diseases. J Clin Immunol 2008; 28 (Suppl 1): S20-S28.
54. Westerberg LS, Klein C, Snapper SB. Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency-lessons learned from monogenic disorders in mice and men. Curr Opin Immunol 2008; 20:646-654.
55. Kwon SW, Procter J, Dale JK, et al. Neutrophil and platelet antibodies in autoimmune lymphoproliferative syndrome. Vox Sang 2003; 85:307-312.
56. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ 2003; 10:124-133.
57. Sneller MC, Dale JK, Straus SE. Autoimmune lymphoproliferative syndrome. Curr Opin Rheumatol 2003; 15:417-421.
58. Malphettes M, Gerard L, Carmagnat M, et al., DEFI Study Group. Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis 2009; 49:1329-1338.
59. Carneiro-Sampaio M, Coutinho A. Tolerance and autoimmunity: lessons at the bedside of primary immunodeficiencies. Adv Immunol 2007; 95:51-82
60. Lee YN, Frugoni F, Dobbs K, et al. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J Allergy Clin Immunol 2014; 133:1099-1108; e1012.
61. Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 2001; 97:81-88.
62. Henderson LA, Frugoni F, Hopkins G, et al. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J Allergy Clin Immunol 2013; 132:969-971; e961-e962.
63. Jawad AF, McDonald-Mcginn DM, Zackai E, et al. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr 2001; 139:715-723.
64. Davies K, Stiehm ER, Woo P, et al. Juvenile idiopathic polyarticular arthritis and IgA deficiency in the 22q11 deletion syndrome. J Rheumatol 2001; 28:2326-2334.
65. Davies JK, Telfer P, Cavenagh JD, et al. Autoimmune cytopenias in the 22q11.2 deletion syndrome. Clin Lab Haematol 2003; 25:195-197.
66. Sullivan KE, McDonald-McGinn D, Zackai EH. CD4(+) CD25(+) T-cell production in healthy humans and in patients with thymic hypoplasia. Clin Diagn Lab Immunol 2002; 9:1129-1131.
67. Piliero LM, Sanford AN, McDonald-McGinn DM, et al. T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome. Blood 2004; 103:1020-1025.
68. Jawad AF, Prak EL, Boyer J, et al. A prospective study of influenza vaccination and a comparison of immunologic parameters in children and adults with chromosome 22q11.2 deletion syndrome (digeorge syndrome/velocardiofacial syndrome). J Clin Immunol 2011; 31:927-935.
69. Walport MJ, Davies KA, Morley BJ, et al. Complement deficiency and autoimmunity. Ann N Y Acad Sci 1997; 815:267-281.
70. Sullivan KE, Kim NA, Goldman D, et al. C4A deficiency due to a 2 bp insertion is increased in patients with systemic lupus erythematosus. J Rheumatol 1999; 26:2144-2147.
71. Chatterjee P, Agyemang AF, Alimzhanov MB, et al. Complement C4 maintains peripheral B-cell tolerance in a myeloid cell dependent manner. Eur J Immunol 2013; 43:2441-2450.
72. Johnston RB Jr. Clinical aspects of chronic granulomatous disease. CurrOpin Hematol 2001; 8:17-22.
73. Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol 2007; 148:79-84.
74. De Ravin SS, Naumann N, Cowen EW, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol 2008; 122:1097-1103.
75. Schappi MG, Jaquet V, Belli DC, Krause KH. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol 2008; 30:255-271.
76. Heltzer M, Jawad AF, Rae J, et al. Diminished T cell numbers in patients with chronic granulomatous disease. Clini Immunol 2002; 105:273-278.
77. Bleesing JJ, Souto-Carneiro MM, Savage WJ, et al. Patients with chronic granulomatous disease have a reduced peripheral blood memory B cell compartment. J Immunol 2006; 176:7096-7103.
78. Sanford AN, Suriano AR, Herche D, et al. Abnormal apoptosis in chronic granulomatous disease and autoantibody production characteristic of lupus. Rheumatology (Oxford) 2006; 45:178-181.
79. Liu L, Okada S, Kong XF, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208:1635-1648.
80. Boisson-Dupuis S, Kong XF, Okada S, et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr Opin Immunol 2012; 24:364-378.
81. Sampaio EP, Hsu AP, Pechacek J, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol 2013; 131:1624-1634.
82. Van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365:54-61.
83. Uzel G, Sampaio EP, Lawrence MG, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathyenteropathy- X-linked-like syndrome. J Allergy Clin Immunol 2013; 131: 1611-1623.
84. Kuehn HS, Niemela JE, Rangel-Santos A, et al. Loss-of-function of the protein kinase C delta (PKCdelta) causes a B-cell lymphoproliferative syndrome in humans. Blood 2013; 121:3117-3125.
85. Limnander A, Depeille P, Freedman TS, et al. STIM1, PKC-delta and RasGRP set a threshold for proapoptotic Erk signaling during B cell development. Nat Immunol 2011; 12:425-433.
86. Limnander A, Weiss A. Ca-dependent Ras/Erk signaling mediates negative selection of autoreactive B cells. Small GTPases 2011; 2:282-288.
87. Barsalou J, Saint-Cyr C, Drouin E, et al. High prevalence of primary immune deficiencies in children with autoimmune disorders. Clin Exp Rheumatol 2011; 29:125-130.